Priority Review for InterMune's Pirfenidone NDA Granted by FDA
Submitted by Jason Ramsey on Mon, 01/04/2010 - 20:18
On Monday, InterMune, the biotech firm, confirmed that the US Food and Drug Administration has granted a priority review status to its New Drug Application for pirfenidone, the company's treatment drug for patients suffering from idiopathic pulmonary fibrosis, or IPF.
Latest News
|
|
|
|
|
|
|
|
|
|
|
|
